These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19375311)

  • 1. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
    Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
    Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
    Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
    Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.
    Hughes RO; Walker JK; Rogier DJ; Heasley SE; Blevis-Bal RM; Benson AG; Jacobsen EJ; Cubbage JW; Fobian YM; Owen DR; Freskos JN; Molyneaux JM; Brown DL; Acker BA; Maddux TM; Tollefson MB; Moon JB; Mischke BV; Rumsey JM; Zheng Y; MacInnes A; Bond BR; Yu Y
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5209-13. PubMed ID: 19631533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
    Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
    Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
    Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
    Pissarnitski D
    Med Res Rev; 2006 May; 26(3):369-95. PubMed ID: 16388517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
    Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
    Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
    Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
    Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
    J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
    Jiang W; Sui Z; Macielag MJ; Walsh SP; Fiordeliso JJ; Lanter JC; Guan J; Qiu Y; Kraft P; Bhattacharjee S; Craig E; Haynes-Johnson D; John TM; Clancy J
    J Med Chem; 2003 Jan; 46(3):441-4. PubMed ID: 12540243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
    Giovannoni MP; Vergelli C; Biancalani C; Cesari N; Graziano A; Biagini P; Gracia J; Gavaldà A; Dal Piaz V
    J Med Chem; 2006 Aug; 49(17):5363-71. PubMed ID: 16913726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
    Srivani P; Srinivas E; Raghu R; Sastry GN
    J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase type 5 inhibitors: state of the therapeutic class.
    Carson CC
    Urol Clin North Am; 2007 Nov; 34(4):507-15, vi. PubMed ID: 17983891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
    Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
    J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.
    Ukita T; Nakamura Y; Kubo A; Yamamoto Y; Takahashi M; Kotera J; Ikeo T
    J Med Chem; 1999 Apr; 42(7):1293-305. PubMed ID: 10197972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.